More importantly, unlike TAN in untreated tumors, which possess an N2 tumor-promoting phenotype, neutrophils recruited to the tumor in mice treated with a TGFβ signaling blocker possess an N1 anti-tumor phenotype. This evidence concerns the gene TGFB1 and neoplasm.